$SBRA

Sabra Health Care REIT, Inc. (SBRA): Results of Operations and Financial Condition

Sabra Health Care REIT, Inc. (SBRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE SABRA REPORTS SECOND QUARTER 2026 RESULTS; REITERATES 2026 GUIDANCE TUSTIN, CA, August 3, 2026 — Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the second quarter of 202

Original reporting
Published Aug 3, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SBRA
Neutral
medium confidence
Mentioned
$SBRA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBRANeutralMed
01

Why it matters

Traders can use the disclosed 2026 per-share guidance ranges and the Q2 reconciliation to update models for normalized earnings power and the expected drag from loan-loss reserves, lease termination, and non-cash adjustments.

02

Market read

This filing is a direct update to 2026 outlook and includes the components behind Q2 normalized earnings, which can affect valuation multiples and near-term positioning in healthcare REITs.

03

What to watch

The excerpt highlights assumptions (same-store Senior Housing - Managed Cash NOI growth low to mid-teens, triple-net Cash NOI low-single-digit) and a specific share-count basis; deviations in tenant transitions or interest-rate/financing costs could matter more than the headline ranges.

Relevance 7/10Novelty 6/10Timing: post-close filing today, before next earnings/credit-market repricing

Background

The SEC 8-K includes Item 2.02 results of operations and financial condition, with non-GAAP reconciliations and 2026 outlook for FFO, Normalized FFO, AFFO, and Normalized AFFO.

Company-level read

Ticker impact

$SBRANeutralMedium confidence
Context

Sabra Health Care REIT provided 2026 FFO and AFFO per-share guidance ranges and detailed Q2 2026 FFO/AFFO reconciliation items.

Expected impact

Near-term price reaction is likely modest unless the market had materially different expectations for 2026 Normalized FFO/AFFO or the reserve/termination dynamics.

Evidence & confidence

This is an SEC 8-K with explicit guidance ranges (Normalized FFO $1.53-$1.55, Normalized AFFO $1.59-$1.61) plus Q2 reconciliation showing large swings in FFO vs net income, but the excerpt does not include consensus comparisons or a new discrete event beyond the filing itself.

Market effects

Guidance for a senior housing REIT with triple-net exposure can influence read-across assumptions for cash NOI growth and reserve intensity across the healthcare REIT group.

No specific regional exposure changes are disclosed in the excerpt.

Limited global relevance; primarily affects US healthcare REIT sentiment and credit spread expectations.

Counterpoint

Normalized metrics can mask underlying cash-flow stress if loan-loss reserves and lease termination costs remain elevated, so guidance may not fully de-risk credit risk.

Key entities

  • Sabra Health Care REIT, Inc.

    Provided Q2 2026 non-GAAP reconciliations and 2026 guidance ranges for FFO/Normalized FFO and AFFO/Normalized AFFO.

Related articles

$SBRAMedAI 8/10

Why Sabra Health Care REIT Stock Soared Today

Sabra Health Care REIT (SBRA) shares rose over 10% after the company issued an operational update. Sabra said it signed letters of intent to retenant 26 Avamere properties, targeting $53M annual rent versus $41M prior. It also arranged to retire a $300M RCA mortgage with $200M cash. Sabra raised 2026 guidance to $0.37-$0.39 headline net income and $1.59-$1.61 normalized AFFO.

$UNFIMedAI 8/10

United Natural Foods (UNFI) Calls the Bottom and Guides for Growth Again

United Natural Foods (UNFI) reported Q4 adjusted EPS of $0.69, beating estimates, but revenue of $7.64B missed expectations. The company guided fiscal 2027 sales to $31.2B-$31.8B, up from $31.15B in 2026. Adjusted EBITDA rose 27% to $701M, and free cash flow hit a record $323M. Management expects fiscal 2027 adjusted EPS of $3.00-$3.50. Hedge fund interest declined in Q2.

MedAI 8/10

LuxExperience B.V. Q4 2026 Earnings Call Summary

LuxExperience B.V. reported Q4 2026 earnings, highlighting EBITDA break-even 15 months post-acquisition. Mytheresa reached EUR 1 billion in sales, while NET-A-PORTER and MR PORTER returned to growth. YOOX cut losses by half. Management expects 2%-3% EBITDA margins in FY 2027 and EUR 4 billion in net sales by 2028. The company improved operational efficiency and strengthened its financial position.

$MOVMed

Movado’s Turnaround Gains Momentum

Movado Group (NYSE: MOV) reported two consecutive quarters of earnings beats, with shares up 60% year-to-date. Analysts rate it a Strong Buy, with an average price target of $40, implying 22% upside. The company benefited from tariff refunds and a shift in consumer preferences toward traditional watches. However, investors should consider potential margin pressures and competition from smartwatches.